Pathology platform for heart and lung tissue and Liquid Biobanking

对于KFO的第二个资助期，我们(汉诺威联合生物库-HUB和MHH病理研究所的Jonigk工作组)将受益于在生物材料收集和保存(组织、细胞、微生物和体液)方面的多年经验以及我们从日常工作和心脏和肺研究的组织病理学和分子病理学专业知识的翻译。这包括建立独特的基础设施，用于快速处理新鲜人体组织和体液，以及生物库、长期储存和提供现有网络和专门知识。此外，通过我们的组织病理学和分子专业知识，我们将支持KFO研究人员分析实验产生的人类和动物组织样本。因此，我们正在从人和动物的心脏和肺中产生容易获得、经过专家评估和极其有价值的组织，以及标准化的液体样本。这将为KFO和相关研究小组增加价值。所有现有的KFO样品都以标准化和质量保证的方式储存。此外，还将产生新的生物材料：i)HUB，约为每年2,000份血清和血浆样本，每位患者一件EDTA Buffy外套，ii)约2700个隔室特定的再处理组织样本(每个LVAD植入约10个样本，每个心脏外植体约60个样本)。为了向KFO研究人员提供现有样品和样品质量的全面概述，将实施一个样品平台(CentraXXand PathoPro之间的接口)，在该平台中可以看到所有KFO样品。从这个样本平台，样本数据将定期传输到KFO数据库(Filemaker)。

For the second funding period of KFO we (Hannover Unified Biobank - HUB and the working group Jonigk of the Institute of Pathology of the MHH) will benefit from many years of experience inbiomaterial collection and preservation (tissues, cells, microorganisms and body fluids) as well as our histopathological and molecular pathological expertise from routine work and heart and lung Research in translation from "bench to bed". This includes an established and unique infrastructure for the rapid processing of fresh human tissue and body fluids, as well as biobanking, long-term storage and the provision of existing networks and expertise. In addition, through our histopathological and molecular expertise we will support KFO-researchers in analyzing human and animal tissue samples generated from experiments. We are thus generating readily available, expertassessed and extremely valuable tissues from human and animal hearts and lungs, as well as standardized fluid samples. This will add value to KFO and the related research groups. All existing KFO samples are stored in a standardized and quality-assured way. Additional, new biomaterials will be generated: i) HUB with approx. 2,000 serum and plasma samples per year and one EDTA buffy coat per patient, ii) Pathology with approx. 2,700 compartment-specific reprocessed tissue samples (per LVAD implantation approx. 10 samples, per heart explant about 60 samples). To provide a comprehensive overview of available samples and sample quality for KFO researchers, a sample platform (interface between CentraXXand PathoPro) will be implemented, in which all KFO samples are visible. From this sample platform, sample data will be periodically transmitted to the KFO database (Filemaker).